A Phase 4 interventional study of Indomethacin, celecoxib, esomeprazole in Colorectal Cancer, sponsored by Göteborg University. Completed at 1 site in Sweden. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-04-02.
Sponsored by Göteborg University · Phase 4, Interventional, and Treatment
The study is designed to evaluate effects of NSAIDs on immune activity inside and close to tumor tissue in patients with colorectal cancer.
Study and control patients are randomized to receive preoperative treatment with indomethacin or celecoxib compared to sham treatment.Tumor biopsies are taken at operation and used for analyses of tumor immunity and gene expression.
5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.
This study's enrollment of 28 is below the median of 77 across 4,123 interventional studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →Göteborg University is the lead sponsor of 265 studies on the registry; 46 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Treatment with indomethacin or celecoxib
Drug: Indomethacin, celecoxib, esomeprazole
Sham treatment
Drug: Indomethacin, celecoxib, esomeprazole
Immune reactivity
Time frame: Acute evaluations
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Göteborg University